2024
Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma
Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024, 35: 724-732. PMID: 38992916, DOI: 10.1111/cyt.13413.Peer-Reviewed Original ResearchHigh-grade papillary urothelial carcinomaLow-grade papillary urothelial carcinomaPapillary urothelial carcinomaUrothelial carcinomaVoided urine samplesCytomorphologic featuresBenign casesUrine samplesUrine specimensNuclear enlargementVoided urine specimensHigh-grade transformationNuclear-to-cytoplasmic (N/CIrregular nuclear membranesUrine cytologyRetrospective reviewHistopathological diagnosisCytomorphologic characteristicsCytomorphological distinctionFrequent recurrenceCytologic featuresCarcinomaBenign conditionsAccurate diagnosisHigh N/C ratioRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2023
Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUC
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease oneMP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY
Khajir G, Kumar D, Rahman S, Leapman M, Levi A, Humphrey P, Sprenkle P. MP45-09 DISCRIMINATIVE SIGNIFICANCE OF PROSTATE BIOPSY DECIPHER SCORE TO PREDICT ADVERSE PATHOLOGY AND PATHOLOGICAL DISCORDANCE AT RADICAL PROSTATECTOMY. Journal Of Urology 2022, 207: e765. DOI: 10.1097/ju.0000000000002611.09.Peer-Reviewed Original ResearchDistribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2021
International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer
Wibmer AG, Kattan MW, Alessandrino F, Baur ADJ, Boesen L, Franco FB, Bonekamp D, Campa R, Cash H, Catalá V, Crouzet S, Dinnoo S, Eastham J, Fennessy FM, Ghabili K, Hohenfellner M, Levi AW, Ji X, Løgager V, Margolis DJ, Moldovan PC, Panebianco V, Penzkofer T, Puech P, Radtke JP, Rouvière O, Schlemmer HP, Sprenkle PC, Tempany CM, Vilanova JC, Weinreb J, Hricak H, Shukla-Dave A. International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer. Cancers 2021, 13: 2627. PMID: 34071842, PMCID: PMC8198352, DOI: 10.3390/cancers13112627.Peer-Reviewed Original ResearchExtraprostatic extensionProstate cancerProstate-specific antigen densityLogistic regression modelsSide-specific extraprostatic extensionConsecutive patientsMRI findingsPatient ageNomogram modelMRI featuresMRI variablesAntigen densityBiopsy dataProstatectomy specimensBenchmark modelMulti-site studyMulti-site initiativesNomogramCancerCharacteristic curveBiopsyPatientsStatistical modelRegression modelsImaging-derived dataExtent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage.
Paulson N, Vollmer RT, Humphrey PA, Sprenkle PC, Onofrey J, Huber S, Amirkhiz K, Levi AW. Extent of High-Grade Prostatic Adenocarcinoma in Multiparametric Magnetic Resonance Imaging-Targeted Biopsy Enhances Prediction of Pathologic Stage. Archives Of Pathology & Laboratory Medicine 2021, 146: 201-204. PMID: 34015819, DOI: 10.5858/arpa.2020-0568-oa.Peer-Reviewed Original ResearchConceptsMpMRI-targeted biopsiesHigh-grade prostatic adenocarcinomaMultiparametric magnetic resonance imagingHG PCaRadical prostatectomyHigh-grade groupMagnetic resonance imagingPathologic stageRP outcomesProstatic adenocarcinomaGrade Group 2 diseaseResonance imagingGrade groupProstate-confined diseaseSeminal vesicle involvementLymph node metastasisHigher pathologic stageAdditional predictive valueLogistic regression modelsLinear millimeterNode metastasisRetrospective reviewAdverse outcomesTargeted biopsiesProstate biopsyAn independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy
Perincheri S, Levi AW, Celli R, Gershkovich P, Rimm D, Morrow JS, Rothrock B, Raciti P, Klimstra D, Sinard J. An independent assessment of an artificial intelligence system for prostate cancer detection shows strong diagnostic accuracy. Modern Pathology 2021, 34: 1588-1595. PMID: 33782551, PMCID: PMC8295034, DOI: 10.1038/s41379-021-00794-x.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterCore biopsyPredictive valueDiagnostic accuracyProstate core needle biopsiesCore needle biopsySurgical pathology practiceNegative predictive valueProstate core biopsiesPositive predictive valueProstate cancer detectionStrong diagnostic accuracyPoor quality scansCancer detectionCancer CenterProstate biopsyLeading causeNeedle biopsyTransrectal approachProstate cancerProstatic adenocarcinomaProstate carcinomaBiopsyPathology practiceProstateHigh-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests
Zuo T, Levi AW, Lin Q, Abi-Raad R, Adeniran AJ, Cai G. High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests. American Journal Of Clinical Pathology 2021, 156: 569-576. PMID: 33728437, DOI: 10.1093/ajcp/aqaa265.Peer-Reviewed Original ResearchConceptsPositive hrHPV resultsCervical intraepithelial neoplasiaHrHPV resultsHrHPV testingCIN2-3Intraepithelial neoplasiaPapanicolaou testCervical carcinomaHigh risk human papillomavirus statusHigh-risk human papillomavirus (hrHPV) testingHigh-grade cervical intraepithelial neoplasiaLow-grade cervical intraepithelial neoplasiaHuman papillomavirus testingHuman papillomavirus (HPV) statusManagement of patientsAbnormal glandular cellsHPV genotypesHPV subtypesAGC casesPap testFollow-upHistologic followHigh lesionsType 16Reactive changesDoubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy
Ghabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, Sprenkle PC. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.Peer-Reviewed Original ResearchBiopsy scoreRadical prostatectomyActive surveillanceBiopsy Gleason grade groupGleason grade group 2Gleason grade group 4Low-risk prostate cancerActive surveillance populationGrade group 4Subsequent surveillance biopsiesOrgan-confined diseaseGrade group 2Gleason grade groupLow-risk categoryBiopsy reclassificationDisease reclassificationSurveillance biopsiesFinal pathologyThird biopsySecond biopsySurveillance populationProstate cancerAdverse featuresGroup 2Genomic scoreMeasuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale
Morrow JS, Gershkovich P, Gibson J, Gilshannon M, Kowalski D, Levi AW, Nguyen DX, Rimm DL, Xu ML, Sinard J. Measuring Faculty Effort: A Quantitative Approach That Aligns Personal and Institutional Goals in Pathology at Yale. Academic Pathology 2021, 8: 23742895211047985. PMID: 34646939, PMCID: PMC8504692, DOI: 10.1177/23742895211047985.Peer-Reviewed Original Research
2020
Fine needle aspiration cytology of a neck mass
Gilani SM, Levi A. Fine needle aspiration cytology of a neck mass. Cytopathology 2020, 31: 622-623. PMID: 32569432, DOI: 10.1111/cyt.12878.Peer-Reviewed Original Research
2019
Economics, Regulations, and Trends in Practice
Levi A, Cai G. Economics, Regulations, and Trends in Practice. 2019, 407-412. DOI: 10.1007/978-3-030-21799-0_15.ChaptersPD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2
Martin D, Ghabili* K, Levi A, Humphrey P, Schulam P, Sprenkle P. PD11-11 DECIPHER BIOPSY GENOMIC TEST RELATED TO GLEASON GRADE GROUP INDEPENDENT OF PROSTATE IMAGING REPORTING AND DATA SYSTEM VERSION 2. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000555367.28091.c8.Peer-Reviewed Original Research
2018
Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies
Martin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.Peer-Reviewed Original ResearchConceptsPI-RADSv2 scoreDecipher scoreProstate Imaging ReportingDecipher testingTargeted biopsiesRadical prostatectomyData System version 2 (PI-RADS v2) scoreFavorable intermediate-risk prostate cancerIntermediate-risk prostate cancer patientsGleason Grade Group 1Imaging ReportingIntermediate-risk prostate cancerMultivariable logistic regression analysisHigh-risk diseasePI-RADS 4Grade group 1Gleason grade groupProstate cancer patientsMultiparametric magnetic resonancePI-RADS scoreVersion 2 scoreData System scoreLogistic regression analysisSignificant differencesPI-RADS category
2017
Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion
Syed JS, Nguyen KA, Nawaf CB, Bhagat AM, Huber S, Levi A, Humphrey P, Weinreb JC, Schulam PG, Sprenkle PC. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion–targeted biopsy in patients with a solitary PI-RADS v2–scored lesion. Urologic Oncology Seminars And Original Investigations 2017, 35: 542.e19-542.e24. PMID: 28501565, DOI: 10.1016/j.urolonc.2017.04.011.Peer-Reviewed Original ResearchConceptsPositive predictive valueProstate cancerGleason scoreSuspicious findingsMultiparametric magnetic resonance imagingProstate multiparametric magnetic resonance imagingPeripheral zoneHigh positive predictive valueFusion-targeted biopsyProstate Imaging ReportingPI-RADS v2Category 4 lesionsMagnetic resonance imagingProstate zonal anatomySystematic biopsyProstate biopsyFusion biopsySingle lesionPatientsBiopsyPredictive valueImaging ReportingResonance imagingLesionsCancerNegative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy
Lu AJ, Syed JS, Nguyen KA, Nawaf CB, Rosoff J, Spektor M, Levi A, Humphrey PA, Weinreb JC, Schulam PG, Sprenkle PC. Negative Multiparametric Magnetic Resonance Imaging of the Prostate Predicts Absence of Clinically Significant Prostate Cancer on 12-Core Template Prostate Biopsy. Urology 2017, 105: 118-122. PMID: 28322902, DOI: 10.1016/j.urology.2017.01.048.Peer-Reviewed Original ResearchConceptsMultiparametric magnetic resonance imagingSignificant prostate cancerProstate cancerNegative predictive valueMagnetic resonance imagingSystematic TRUSNegative mpMRIProstate biopsyNegative multiparametric magnetic resonance imagingPredictive valueResonance imagingClinically Significant Prostate CancerDynamic contrast enhancement sequencesTemplate mapping biopsyPrior negative biopsySystematic prostate biopsyOverall cancer detectionProstate-specific antigenTemplate prostate biopsyProstate cancer detectionDiffusion-weighted imagingCancer detectionBiopsy naïveMapping biopsyProstate volumeThe positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.
Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.Peer-Reviewed Original ResearchPI-RADS 4 lesionsPositive predictive valueBiopsy-naïve menNaïve menPredictive valuePI-RADS 3PI-RADS version 2PI-RADS 4Cancer detection rateChi-square testPSA densityEntire cohortMean ageFusion biopsyProstate cancerSingle lesionLesion locationGroup 2Group 1Group 3LesionsAssessment scoresLesion numberCategorical variablesFurther assessment
2016
PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS?
Lu A, Nawaf C, Rosoff J, Weinreb J, Humphrey P, Levi A, Huber S, Sprenkle P. PD15-11 SHOULD WE STILL BIOPSY NEGATIVE MP-MRIS? Journal Of Urology 2016, 195: e393. DOI: 10.1016/j.juro.2016.02.1137.Peer-Reviewed Original Research